References
- Paniz-Mondolfi AE, Colella MT, Negrín DC, Aranzazu N, Oliver M, Reyes-Jaimes O, Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and itraconazole. Med Mycol. 2008;46(2):179–184.
- Sayal SK, Prasad GK, Jawed KZ, Sanghi S, Satyanarayana S. Chromoblastomycosis. Indian J Dermatol Venereol Leprol. 2002;68:233–234.
- Franzen AJ, Cunha MM, Miranda K, Hentschel J, Plattner H, da Silva MB, Ultrastructural characterization of melanosomes of the human pathogenic fungus Fonsecaea pedrosoi. J Struct Biol. 2008;162(1):75–84.
- Damian DL, Barnetson RS, Thompson JF. Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg. 2006;10(1):48–51.
- Gimenes VM, Criado PR, Martins JE, Almeida SR. Cellular immune response of patients with chromoblastomycosis undergoing antifungal therapy. Mycopathologia. 2006; 162(2):97–101.
- Tuffanelli I, Milburn PB. Treatment of chromoblastomycosis. J Am Acad Dermotol. 1991;25(5 Pt 1):869–870.
- Smith C, Barker J, Hay R. A case of chromoblastomycosis responding to treatment with itraconazole. Br J Dermatol. 1993;128:436–439.
- Queiroz-Telles F, Purim KS, Fillus JN, Bordignon GF, Lameira RP, Van Cutsem J, Cauwenbergh G. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992;31:805–812.
- Andrade TS, Castro LG, Nunes RS, Gimenes VM, Cury AE. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses. 2004;47:216–221.
- Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: Novel perspectives. Curr Opin Infect Dis. 2006; 19(2):148–152.
- Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: An in vitro comparison. J Am Acad Dermatol. 1998;38:37–41.
- Gupta AK, Taborda PR, Danzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529–534.
- Bonifaz A, Paredes-Sólis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004;5:247–254.
- Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am. 2003;17(1): 59–85.
- Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(suppl 1):1–10.
- Hamza SH, Mercado PJ, Skelton HG, Smith KJ. An unusual dematiaceous fungal infection of the skin caused by Fonsecaea pedrosoi: A case report and review of the literature. J Cutan Pathol. 2003;30(5):340–343.
- Surash S, Tyagi A, De Hoog GS, Zeng JS, Barton RC, Hobson RP. Cerebral phaeohyphomycosis caused by Fonsecaea monophora. Med Mycol. 2005;43(5):465–472.
- Perfect J, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122–1131.
- Paugam A. The latest data on posaconazole. Med Mal Infect. 2007;37(2):71–76.
- Jurkunas UV, Langston DP, Colby K. Use of voriconazole in the treatment of fungal keratitis. Int Ophthalmol Clin. 2007;47(2):47–59.
- Da Silva JP, Alviano DS, Alviano CS, de Souza W, Travassos LR, Diniz JA, Comparison of Fonsecaea pedrosoi sclerotic cells obtained in vivo and in vitro: Ultrastructure and antigenicity. FEMS Immunol Med Microbiol. 2002;33(1):63–69.
- Sabo JA, Abdel-Rahman SM. Voriconazole: A new traizole antifungal. Ann Pharmacother. 2000;34:1032–1043.
- Johnson L, Kauffman C. Voriconazole: A new triazole antifungal agent. Clin Infect Dis. 2003;36:630–637.